Faculty profile

Kevin Hay

ResearcherDepartment of SurgeryUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Kevin Hay

Researcher

Department of Surgery

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
3 publications in the last five years, latest in 2025.
Principal investigator on 9 research grants (9 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Adoptive Immunotherapy Cell Therapy Graft Versus Host Disease Regulatory T Cells Tolerance Transplantation B-Cell Acute Lymphoblastic Leukemia Cd22

Latest papers

Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis.
Transfusion medicine reviews · 2025
Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.
Acta haematologica · 2025
Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
Systematic reviews · 2023

All 8 publications

Latest funding

Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)
CIHR · 2025 · Principal investigator
$1,216,351
Allogeneic regulatory T cell therapy to prevent graft versus host disease
CIHR · 2024 · Principal investigator
$2,000,000
Targeting metabolic vulnerabilities in childhood cancers using immunotherapy
CIHR · 2023 · Co-investigator
$956,250

All 13 grants and awards

8 publications.

Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis.

Lalu MM, Igweokpala S, Kekre N, Jeffers MS, Montroy J, Ghiasi M, Hay K, McComb S, Weeratna R, Atkins H, Hutton B, Yahya A, Masurekar A, Giguere P, Sabri E, Sobh M, Fergusson DA

Transfusion medicine reviews2025

DOI: 10.1016/j.tmrv.2025.150897 PMID: 40280037

Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.

Bai N, Limvorapitak W, Henderson R, Abou Mourad Y, Chung S, Forrest D, Hay K, Kuchenbauer F, Nantel S, Narayanan S, Nevill T, Power M, Rodrigo J, Roy C, Sanford D, Song K, Stubbins R, Sutherland H, Toze C, White J

Acta haematologica2025

DOI: 10.1159/000541071 PMID: 39197435

Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.

Lalu MM, Kekre N, Montroy J, Ghiasi M, Hay K, McComb S, Weeratna R, Atkins H, Hutton B, Yahya A, Masurekar A, Sobh M, Fergusson DA

Systematic reviews2023

DOI: 10.1186/s13643-022-02158-1 PMID: 36653879

Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study.

Khalife R, Montroy J, Grigor EJM, Fergusson DA, Atkins H, Seftel M, Presseau J, Thavorn K, Holt RA, Hay K, Lalu MM, Kekre N

British journal of haematology2020

DOI: 10.1111/bjh.16940 PMID: 32688454

Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.

Hoiland RL, Stukas S, Cooper J, Thiara S, Chen LYC, Biggs CM, Hay K, Lee AYY, Shojania K, Abdulla A, Wellington CL, Sekhon MS

British journal of haematology2020

DOI: 10.1111/bjh.16961 PMID: 32584416

Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas.

El-Galaly TC, Cheah CY, Kristensen D, Hutchison A, Hay K, Callréus T, Villa D

Acta oncologica (Stockholm, Sweden)2020

DOI: 10.1080/0284186x.2020.1741680 PMID: 32189546

Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma.

Hay K, Lee B, Goktepe O, Connors JM, Sehn LH, Savage KJ, Klasa R, Shenkier T, Gerrie A, Villa D

Leukemia & lymphoma2016First author

DOI: 10.3109/10428194.2015.1055480 PMID: 26010123

Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia.

Lee B, Goktepe O, Hay K, Connors JM, Sehn LH, Savage KJ, Shenkier T, Klasa R, Gerrie A, Villa D

The oncologist2014

DOI: 10.1634/theoncologist.2013-0343 PMID: 24569946

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Adoptive Immunotherapy Dear Professor Hay, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis." (2025), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Kevin Hay

Research

Latest papers

Latest funding

Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis.

Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.

Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.

Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study.

Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.

Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas.

Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma.

Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia.

Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)

Allogeneic regulatory T cell therapy to prevent graft versus host disease

Targeting metabolic vulnerabilities in childhood cancers using immunotherapy

Allogeneic regulatory T cell therapy to prevent chronic graft versus host disease

A Phase I Feasibility and Safety Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Relapsed/Refractory GPNMB-Expressing Solid Tumors

A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)

Development of second-generation radiopharmaceuticals targeting the C-X-C chemokine receptor 4 for imaging and therapy of hematological cancers

A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia

Frequent collaborators

Harold Atkins

Natasha Kekre

Brian Hutton

Kevin Song

Justin Presseau

Kednapa Thavorn